Theratechnologies Inc T.TH

Christian will be presenting at next-gen-conjugates

[scarlet1967]

4:45 pm Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes

• Christian Marsolais
  Senior Vice President & Chief Medical Officer, Theratechnologies Inc.

 

Synopsis

• Understand the rationale for targeting the SORT1 receptor in cancer
• Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform
• Discuss the unique multimodal MOA of this PDC
• Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinations

https://next-gen-conjugates.com/whats-on/day-two/

[Lee430]

Question: Is the last presentation of the day when attendees eyes are kind of glassed over from information overload and probably just looking get out of there to grab some liquid dinner a not so good slot? oh and just a 15 minute slot seems pretty short with no time for Q&A or is that for after the presentation?

[PWIB123]

I was wondering the same thing about that last slot.  

[scarlet1967]

It's the last presentation of the summit so perhaps they decided to register recently. Let's see what he has to say about "emerging clinical".. The first patient was dosed on October 12 and by now had their three consecutive shots followed by a week of rest and the three months observation period. Admittedly it's only one patient as far as we know on the lower dose and it